<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Achondroplasia</z:e> is a common <z:hpo ids='HP_0002652'>skeletal dysplasia</z:hpo> with severe <z:hpo ids='HP_0001510'>growth retardation</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, mutations in the fibroblast growth factor receptor 3 (FGFR3) were identified in patients with <z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">achondroplasia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, 70 of 75 Japanese patients with <z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">achondroplasia</z:e> were found to have a G1138A mutation in FGFR3, and two patients had a G1138C mutation </plain></SENT>
<SENT sid="3" pm="."><plain>Growth hormone therapy was given to 145 patients with <z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">achondroplasia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Significant dose-dependent effects on skeletal growth were obtained, with no long-term adverse effects </plain></SENT>
</text></document>